Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO

Published:2018-05 Issue:5 Volume:120 Page:549-550
ISSN:1081-1206
Container-title:Annals of Allergy, Asthma & Immunology
language:en
Short-container-title:Annals of Allergy, Asthma & Immunology

Author:

Luskin Allan T.,Chipps Bradley E.,Casale Thomas B.,Griffin Noelle M.

Funder

Genentech, Inc.

Roche Group

Novartis Pharma AG

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy,Immunology

Reference10 articles.

1. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO;Oppenheimer;Ann Allergy Asthma Immunol,2017

2. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO;Chipps;Ann Allergy Asthma Immunol,2017

3. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma;Oba;J Allergy Clin Immunol,2004

4. Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis;Luskin;Clinicoecon Outcomes Res,2016

5. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study;Waljee;BMJ,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Best of 2018 in the Annals of Allergy, Asthma, and Immunology;Annals of Allergy, Asthma & Immunology;2019-02

2. Authors' response;Annals of Allergy, Asthma & Immunology;2018-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP